{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:14:13Z","timestamp":1791828853889,"version":"4.3.4"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"SI3","license":[{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pfizer and Lilly"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The objective of this study was to assess the possibility of HBV reactivation (HBVr) in patients with RA under anti-IL-6 treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using PubMed, Scopus and EMBASE, we performed a systematic literature search for articles related to HBVr in RA patients under anti-IL-6 treatment. The search was performed with no date limits and was last updated 28 January 2023. The results from all the databases were combined and duplicates were excluded, as were non-English articles, case reports, position articles, comments, and paediatric studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Our initial search led to 427 articles; 28 were duplicates, 46 non-English, 169 reviews, 31 books\/letters, 25 case reports, and 88 irrelevant to the meta-analysis aim; 21 were excluded due to inadequate information, leaving 19 articles, with a sum of 372 RA patients with chronic HBV (CHB) or resolved HBV infection, for further analysis. The overall risk for HBVr in RA patients with CHB was 6.7%, increasing to 37% when only RA patients with CHB and no antiviral prophylaxis were included. On the contrary, HBVr was close to 0% in RA patients with resolved HBV infection, irrespective of antiviral prophylaxis. All RA patients experiencing HBVr in these studies were successfully managed with antiviral treatment and\/or drug withdrawal.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Overall, anti-IL-6 treatment comes with a significant risk of HBVr in RA patients with CHB; risk is diminished when antiviral prophylaxis is used. In contrast, in RA patients with resolved HBV infection, the risk of HBVr seems to be extremely low. Large, well-designed studies (either controlled trials or multicentre\/international observational studies) are warranted to further validate these results.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/kead243","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T23:09:08Z","timestamp":1698102548000},"page":"SI252-SI259","source":"Crossref","is-referenced-by-count":11,"title":["HBV reactivation in patients with rheumatoid arthritis treated with anti-interleukin-6: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4481-9993","authenticated-orcid":false,"given":"Stamatia","family":"Katelani","sequence":"first","affiliation":[{"name":"Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens , Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4932-7023","authenticated-orcid":false,"given":"George E","family":"Fragoulis","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Propedeutic Clinic, \u201cLaiko\u201d Hospital, National and Kapodistrian University of Athens , Athens, Greece"},{"name":"Institute of Infection, Immunity and Inflammation, University of Glasgow , Scotland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9465-2162","authenticated-orcid":false,"given":"Athanasios-Dimitrios","family":"Bakasis","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens , Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Pouliakis","sequence":"additional","affiliation":[{"name":"2nd Department of Pathology, National and Kapodistrian University of Athens, Medical School, University General Hospital Attikon , Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Nikiphorou","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Atzeni","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina , Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2556-6230","authenticated-orcid":false,"given":"Theodoros","family":"Androutsakos","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens , Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,23]]},"reference":[{"key":"2023121221173052000_kead243-B1","doi-asserted-by":"crossref","first-page":"e002726","DOI":"10.1136\/rmdopen-2022-002726","article-title":"Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"8","author":"Fragoulis","year":"2022","journal-title":"RMD Open"},{"key":"2023121221173052000_kead243-B2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/cld.883","article-title":"Reactivation of hepatitis B virus: a review of clinical guidelines","volume":"15","author":"Myint","year":"2020","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"2023121221173052000_kead243-B3","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"2023121221173052000_kead243-B4","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/14712598.2016.1177017","article-title":"Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders","volume":"16","author":"Vigano","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"2023121221173052000_kead243-B5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology"},{"key":"2023121221173052000_kead243-B6","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/phar.2340","article-title":"Hepatitis B virus reactivation: risk factors and current management strategies","volume":"39","author":"Smalls","year":"2019","journal-title":"Pharmacotherapy"},{"key":"2023121221173052000_kead243-B7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/17474124.2020.1774364","article-title":"Hepatitis B reactivation: diagnosis and management","volume":"14","author":"Huang","year":"2020","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2023121221173052000_kead243-B8","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"2023121221173052000_kead243-B9","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"2023121221173052000_kead243-B10","doi-asserted-by":"crossref","first-page":"288","DOI":"10.5009\/gnl210551","article-title":"Risk of Hepatitis B Virus (HBV) reactivation in HBsAg-negative, anti-HBc-negative patients receiving rituximab for autoimmune diseases in HBV endemic areas","volume":"17","author":"Lan","year":"2023","journal-title":"Gut Liver"},{"key":"2023121221173052000_kead243-B11","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11739-021-02836-3","article-title":"Long-term safety of rituximab in rheumatic patients with previously resolved hepatitis B virus infection","volume":"17","author":"Barone","year":"2022","journal-title":"Intern Emerg Med"},{"key":"2023121221173052000_kead243-B12","first-page":"831","article-title":"Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative\/HBcAb-positive patients receiving rituximab for rheumatoid arthritis","volume":"35","author":"Tien","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2023121221173052000_kead243-B13","doi-asserted-by":"crossref","first-page":"926836","DOI":"10.1155\/2014\/926836","article-title":"HBV reactivation in patients treated with antitumor necrosis factor-alpha (TNF-\u03b1) agents for rheumatic and dermatologic conditions: a systematic review and meta-analysis","volume":"2014","author":"Cantini","year":"2014","journal-title":"Int J Rheumatol"},{"key":"2023121221173052000_kead243-B14","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/1756-185X.14034","article-title":"Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-\u03b1 therapy","volume":"24","author":"Fidan","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"2023121221173052000_kead243-B15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.clim.2018.03.013","article-title":"Patients with core antibody positive and surface antigen negative Hepatitis B (anti-HBc+, HBsAg-) on anti-TNF therapy have a low rate of reactivation","volume":"191","author":"Clarke","year":"2018","journal-title":"Clin Immunol"},{"key":"2023121221173052000_kead243-B16","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/ard-2022-222784","article-title":"Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update","volume":"82","author":"Aletaha","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2023121221173052000_kead243-B17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/annrheumdis-2021-220973","article-title":"EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis","volume":"81","author":"Nagy","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2023121221173052000_kead243-B18","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1159\/000430386","article-title":"Involvement of interleukin 6 in hepatitis B viral infection","volume":"37","author":"Xia","year":"2015","journal-title":"Cell Physiol Biochem"},{"key":"2023121221173052000_kead243-B19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.14218\/JCTH.2015.00024","article-title":"IL-6 plays a crucial role in HBV infection","volume":"3","author":"Lan","year":"2015","journal-title":"J Clin Transl Hepatol"},{"key":"2023121221173052000_kead243-B20","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2023121221173052000_kead243-B21","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"2023121221173052000_kead243-B22","author":"Wells","year":"2021"},{"key":"2023121221173052000_kead243-B23","author":"The R Project for Statistical Computing","year":"2021"},{"key":"2023121221173052000_kead243-B24","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"2023121221173052000_kead243-B25","first-page":"40","article-title":"meta: an R package for meta-analysis","volume":"7","author":"Schwarzer","year":"2007","journal-title":"R news"},{"key":"2023121221173052000_kead243-B26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"2023121221173052000_kead243-B27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.6000\/1929-6029.2015.04.01.6","article-title":"Estimating mean and standard deviation from the sample size, three quartiles, minimum, and maximum","volume":"4","author":"Bland","year":"2015","journal-title":"Int J Stat Med Res"},{"key":"2023121221173052000_kead243-B28","author":"Deepanshu","year":"2021"},{"key":"2023121221173052000_kead243-B29","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3109\/s10165-011-0458-z","article-title":"Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and\/or nonbiological disease-modifying antirheumatic drugs","volume":"21","author":"Mori","year":"2011","journal-title":"Modern Rheumatol"},{"key":"2023121221173052000_kead243-B30","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.3899\/jrheum.110289","article-title":"Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in Hepatitis B surface antigen\u2013negative cases","volume":"38","author":"Kato","year":"2011","journal-title":"J Rheumatol"},{"key":"2023121221173052000_kead243-B31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/s10165-010-0337-z","article-title":"Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients","volume":"21","author":"Urata","year":"2011","journal-title":"Mod Rheumatol"},{"key":"2023121221173052000_kead243-B32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3899\/jrheum.130466","article-title":"Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan","volume":"41","author":"Koike","year":"2014","journal-title":"J Rheumatol"},{"key":"2023121221173052000_kead243-B33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/hep.27716","article-title":"Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection","volume":"62","author":"Barone","year":"2015","journal-title":"Hepatology"},{"key":"2023121221173052000_kead243-B34","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/1756-185X.12359","article-title":"Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs","volume":"19","author":"Nakamura","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"2023121221173052000_kead243-B35","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/annrheumdis-2016-209973","article-title":"Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan","volume":"76","author":"Fukuda","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023121221173052000_kead243-B36","first-page":"566","article-title":"Hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologics treatment","volume":"215","author":"Chen","year":"2017","journal-title":"J Infect Dis"},{"key":"2023121221173052000_kead243-B37","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/1756-185X.13010","article-title":"Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation","volume":"20","author":"Chen","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"2023121221173052000_kead243-B38","doi-asserted-by":"crossref","first-page":"194","DOI":"10.5152\/eurjrheum.2017.17003","article-title":"Biological therapy in arthritis patients with hepatitis B or C infection: a multicenter retrospective case series","volume":"4","author":"Abdulaziz","year":"2017","journal-title":"Eur J Rheumatol"},{"key":"2023121221173052000_kead243-B39","first-page":"102","article-title":"Liver safety of non-tumour necrosis factor inhibitors in rheumatic patients with past hepatitis B virus infection: an observational, controlled, long-term study","volume":"36","author":"Papalopoulos","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2023121221173052000_kead243-B40","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3349\/ymj.2018.59.3.452","article-title":"Safety of tocilizumab in rheumatoid arthritis patients with resolved hepatitis B virus infection: data from real-world experience","volume":"59","author":"Ahn","year":"2018","journal-title":"Yonsei Med J"},{"key":"2023121221173052000_kead243-B41","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1007\/s10067-018-4295-8","article-title":"Management of anti-HBc\u2013positive patients with rheumatic diseases treated with disease-modifying antirheumatic drugs\u2014a single-center analysis of 2054 patients","volume":"37","author":"Schwaneck","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2023121221173052000_kead243-B42","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/1756-185X.13401","article-title":"Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease\u2013modifying antirheumatic drugs","volume":"22","author":"Watanabe","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"2023121221173052000_kead243-B43","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jmii.2017.04.002","article-title":"Safety and effectiveness of tocilizumab in treating patients with rheumatoid arthritis \u2013 a three-year study in Taiwan","volume":"52","author":"Lin","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"2023121221173052000_kead243-B44","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1136\/annrheumdis-2020-218289","article-title":"The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series","volume":"80","author":"Serling-Boyd","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023121221173052000_kead243-B45","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1007\/s10620-020-06725-1","article-title":"Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing tocilizumab-containing treatment","volume":"66","author":"Kuo","year":"2021","journal-title":"Dig Dis Sci"},{"key":"2023121221173052000_kead243-B46","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s42358-021-00173-9","article-title":"Risk factors for losing hepatitis B virus surface antibody in patients with HBV surface antigen negative\/surface antibody positive serostatus receiving biologic disease\u2013modifying anti-rheumatic drugs: a nested case\u2013control study","volume":"61","author":"Hung","year":"2021","journal-title":"Adv Rheumatol"},{"key":"2023121221173052000_kead243-B47","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3390\/jcm12010086","article-title":"The impact of b\/tsDMARD dose reduction on chronic hepatitis B in rheumatoid arthritis patients: a two-center long-term safety analysis","volume":"12","author":"Chen","year":"2022","journal-title":"J Clin Med"},{"key":"2023121221173052000_kead243-B48","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","article-title":"IL-6: regulator of Treg\/Th17 balance","volume":"40","author":"Kimura","year":"2010","journal-title":"Eur J Immunol"},{"key":"2023121221173052000_kead243-B49","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12016-014-8465-4","article-title":"Cytokine-mediated immunopathogenesis of hepatitis B virus infections","volume":"50","author":"Li","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"2023121221173052000_kead243-B50","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1423-0127-16-41","article-title":"HBV replication is significantly reduced by IL-6","volume":"16","author":"Kuo","year":"2009","journal-title":"J Biomed Sci"},{"key":"2023121221173052000_kead243-B51","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/hep.23226","article-title":"Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection","volume":"50","author":"Hosel","year":"2009","journal-title":"Hepatology"},{"key":"2023121221173052000_kead243-B52","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.virol.2015.02.026","article-title":"Interleukin 6 inhibits HBV entry through NTCP down regulation","volume":"481","author":"Bouezzedine","year":"2015","journal-title":"Virology"},{"key":"2023121221173052000_kead243-B53","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2023121221173052000_kead243-B54","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2023121221173052000_kead243-B55","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/acr.23346","article-title":"Risk of hepatitis B virus reactivation in patients with inflammatory arthritis receiving disease-modifying antirheumatic drugs: a systematic review and meta-analysis","volume":"70","author":"Lin","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023121221173052000_kead243-B56","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s00535-020-01680-0","article-title":"Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review","volume":"55","author":"de Fraga","year":"2020","journal-title":"J Gastroenterol"},{"key":"2023121221173052000_kead243-B57","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1038\/s41598-020-59406-4","article-title":"Moderate risk of hepatitis B virus reactivation in HBsAg\u2013\/HBcAb+ carriers receiving rituximab for rheumatoid arthritis","volume":"10","author":"Kuo","year":"2020","journal-title":"Sci Rep"},{"key":"2023121221173052000_kead243-B58","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/1756-185X.13582","article-title":"Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: a long-term, real-world observation","volume":"22","author":"Chen","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"2023121221173052000_kead243-B59","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle\u2013Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"2023121221173052000_kead243-B60","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","article-title":"EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome","volume":"81","author":"Drosos","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2023121221173052000_kead243-B61","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/annrheumdis-2022-222155","article-title":"EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases","volume":"82","author":"Krieckaert","year":"2023","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/SI3\/SI252\/54359363\/kead243.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/SI3\/SI252\/54359363\/kead243.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T21:18:13Z","timestamp":1702415893000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/SI3\/SI252\/7328908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,1]]},"references-count":61,"journal-issue":{"issue":"SI3","published-online":{"date-parts":[[2023,10,23]]},"published-print":{"date-parts":[[2023,10,23]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kead243","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10,1]]},"published":{"date-parts":[[2023,10,1]]}}}